Last reviewed · How we verify
Comparator: Infanrix™
Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.
Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters).
At a glance
| Generic name | Comparator: Infanrix™ |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Combination vaccine (inactivated toxoid and acellular pertussis) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Infanrix contains inactivated toxoids of diphtheria and tetanus, along with acellular pertussis antigens, which trigger adaptive immune responses without causing disease. The vaccine primes both humoral (antibody) and cellular immunity to protect against these three bacterial infections. It is administered as part of the standard childhood immunization schedule.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters)
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fussiness or irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (PHASE2)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (PHASE3)
- Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (PHASE2)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (PHASE3)
- A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) (PHASE3)
- Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Infanrix™ CI brief — competitive landscape report
- Comparator: Infanrix™ updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI